Patients were randomized to either acupuncture, sham acupuncture, or waiting list control. Acupuncture and sham acupuncture were administered by specific physicians and contains 12 sessions per patient over 8 weeks. The sham treatment contains needles placed at non-acupuncture points. Individuals were treated at 18 outpatient centers in Germany. Patients completed headache diaries from 4 weeks before to 12 weeks after randomization and from week 21 to 24 after randomization. Related StoriesCalcitonin-gene related peptide antibody inhibition displays migraine prevention promiseNew research offers first clinical tips for headache diagnosis in pregnant womenAlexander Technique or acupuncture can relieve chronic neck painThe researchers found that between baseline and weeks 9 to 12, the common number of days with headache of severe or moderate intensity decreased by 2.2 days from a baseline of 5.2 times in the acupuncture group compared with a decrease to 2.2 times from a baseline of 5.0 days in the sham acupuncture group, and by 0.8 times from a baseline of 5.4 days in the waiting list group.Meals and Drug Administration relating to AMRI’s Burlington, Massachusetts aseptic finish-and-fill service, which stated the corrective activities proposed by AMRI in its written response to an August 2010 warning letter and a June 2011 Form 483, should address the observations made by FDA investigators adequately. A signed contract with Innovative Antibiotics, a Swedish-based drug discovery company, to supply chemistry and biology solutions to progress their antibacterial programs. The hire of Subramanyam Maddala as President, India Operations, to lead AMRI’s Indian API developing functions and manage AMRI service procedures in Hyderabad and Aurangabad, India. The hire of Charles Jensen, Ph.D. As Director of Medication Metabolism and Pharmacokinetics, strengthening AMRI’s capabilities in DMPK and additional enhancing its global system of integrated discovery biology and chemistry providers.